1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Phosphatase

Phosphatase

Phosphatases are enzyme that remove a phosphate group from a protein. Protein tyrosine phosphatases (PTPs) comprise a diverse family of transmembrane and cytoplasmic enzymes. PTPs play an important role in regulating the proliferative activity of cells and the integrity of cell-cell and cell-matrix contacts. Protein tyrosine phosphatase 1B (PTP1B) is a non-receptor PTP frequently associated with the endoplasmic reticulum and vesicles subjacent to the plasma membrane. PTP1B as a key negative regulator of leptin receptor pathways has been an attractive therapeutic target for the treatment of type 2 diabetes mellitus and obesity. Four major serine/threonine-specific protein phosphatase catalytic subunits are present in the cytoplasm of animal cells. Three of these enzymes, PP1, PP2A, and PP2B, are members of the same gene family, while PP2C appears to be distinct.The alkaline phosphatases comprise a heterogeneous group of enzymes that are widely distributed in mammalian cells. Acid phosphatase enzymes catalyze the hydrolysis of phosphate monoesters following the general equation.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-125539
    Roridin E
    Inhibitor 99.82%
    Roridin E is a glucose-6-phosphatase (G6Pase) inhibitor and antibiotic, and is a metabolic byproduct of Roridin A (HY-N9599). Roridin E induces significant oxidative stress, characterized by depletion of glutathione in vivo, induction of hepatic lipid peroxidation, and inhibition of renal superoxide dismutase activity. Roridin E reduces blood glucose levels in rats, but exhibits acute toxicity (which is enhanced when co-administered with linoleic acid (HY-N0729)) and causes hepatotoxicity in male albino mice. Roridin E induces a decrease in total blood protein and increases in the levels of total lipids, γ-glutamyltransferase, alkaline phosphatase, and 5'-nucleotidase. Roridin E can be isolated from molds, and possesses cytostatic and antifungal activities similar to those of Verrucarin A (HY-107426) and Roridin A. Roridin E exhibits in vivo activity in rodents and is commonly used in hepatotoxicity-related studies.
    Roridin E
  • HY-18756A
    NSC-87877 disodium
    Inhibitor 98.0%
    NSC-87877 disodium is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC50 values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).
    NSC-87877 disodium
  • HY-128682
    PGAM1-IN-2
    Inhibitor 98.02%
    PGAM1-IN-2 is a phosphoglycerate mutase 1 (PGAM1) inhibitor with an IC50 of 2.1 μM.
    PGAM1-IN-2
  • HY-136268
    AQX-435
    Activator 99.15%
    AQX-435 is a potent SHIP1 phosphatase activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth.
    AQX-435
  • HY-126246
    CDC25B-IN-1
    Inhibitor 98.12%
    CDC25B-IN-1 (compound 4a) is a potent inhibitor of cell division cycle 25B (CDC25B) phosphatase, with a Ki of 8.5 μM. CDC25B-IN-1 potently inhibits cell proliferation and colony formation, causes an increase of the G2/M phase.
    CDC25B-IN-1
  • HY-N11441
    cis-Ferulic acid 4-O-β-D-glucopyranoside
    Inhibitor 99.30%
    cis-Ferulic acid 4-O-β-D-glucopyranoside (compound 7) is a phenolic glycosid, which can be isolated from Nitraria sibirica.. cis-Ferulic acid 4-O-β-D-glucopyranoside exhibits antioxidant activity and potent inhibitory effect on Phosphatase PTP1B.
    cis-Ferulic acid 4-O-β-D-glucopyranoside
  • HY-108944
    LYP-IN-1
    Inhibitor 99.82%
    LYP-IN-1 is a potent, selective and specific LYP inhibitor with a Ki and an IC50 of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC50=5 μM) and SHP2 (IC50=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders. LYP-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LYP-IN-1
  • HY-137175A
    CDC25B-IN-2
    Inhibitor
    CDC25B-IN-2 is a potent cdc25B inhibitor.
    CDC25B-IN-2
  • HY-123966A
    MY33-3 hydrochloride
    Inhibitor 99.32%
    MY33-3 hydrochloride is a potent and selective inhibitor of receptor protein tyrosine phosphatase (RPTP)β/ζ, with an IC50 of ~0.1 μM. MY33-3 hydrochloride also inhibits PTP-1B (IC50 ~0.7 μM). MY33-3 hydrochloride can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction.
    MY33-3 hydrochloride
  • HY-160791B
    Claramine hydrochloride
    Inhibitor 99.58%
    Claramine hydrochloride is a steroid polyamine with blood-brain barrier permeability. Claramine hydrochloride can regulate the properties of lipid membranes and protect cells from various biological toxins, including misfolded protein oligomers and biological protein-based toxins.
    Claramine hydrochloride
  • HY-153077
    PFKFB3-IN-2
    Inhibitor 99.86%
    PFKFB3-IN-2 is a 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) inhibitor. PFKFB3-IN-2 has potential applications in cancer, neurodegenerative diseases, autoimmune diseases, inflammatory diseases, multiple sclerosis, metabolic diseases, angiogenesis inhibition and other diseases.
    PFKFB3-IN-2
  • HY-B2203
    Monocalcium glycerophosphate
    Inhibitor 98.0%
    Monocalcium glycerophosphate is an inhibitor of intestinal alkaline phosphatase F3, and it has anti-cavity properties. Monocalcium glycerophosphate is a source of calcium and phosphorus in total parenteral nutrition solutions, helps prevent the mineralization and development of bones from intravenous nutrition, and maintains the integrity of the intestinal epithelium.
    Monocalcium glycerophosphate
  • HY-B0019C
    (R)-Azasetron besylate
    Inhibitor 98.78%
    (R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage.
    (R)-Azasetron besylate
  • HY-155847
    LYP-IN-3
    Inhibitor 99.80%
    LYP-IN-3 is a selective, orally active and reversible lymphoid-tyrosine phosphatase (LYP) inhibitor (IC50 = 2.55 μM, Ki = 0.93 μM). D34 exhibits high selectivity of PTP1B, PTPN12, PTPN5 and SSH2. LYP-IN-3 regulates the T-cell receptor (TCR) signaling by specifically inhibiting LYP. LYP-IN-3 does not significantly inhibit MC38 cell viability; its anti-tumor effect stems from immune regulation. LYP-IN-3 can significantly upregulate PD-L1 or PD-1 expression in different immune cells. LYP-IN-3 facilitates T-cell infiltration and enhances T-cell functions. LYP-IN-3 synergizes with PD-L1 blockade can significantly improve colorectal tumor regression. LYP-IN-3 can be used for the study of colorectal cancer.
    LYP-IN-3
  • HY-P991222
    AMG-529
    Activator
    AMG-529 is a humanized monoclonal antibody against ASGR1 that binds to ASGR1, blocks ligand binding, and causes a dose-dependent increase in ALP (a biomarker of ASGR1 inhibition). AMG-529 can be used for the research of cardiovascular diseases.
    AMG-529
  • HY-121879
    SHP836
    Inhibitor 98.36%
    SHP836 is a SHP2 allosteric inhibitor, with an IC50 of 12 μM for the full length SHP2.
    SHP836
  • HY-128591
    DIPQUO
    Activator 98.70%
    DIPQUO is an activator of the bone marker alkaline phosphatase (ALP), with an EC50 of 6.27 μM in C2C12 cells. DIPQUO promotes mouse and human osteoblast differentiation via activation of p38 MAPK-β.
    DIPQUO
  • HY-112700
    SHIP2-IN-1
    Inhibitor 98.66%
    SHIP2-IN-1 is a potent SHIP2 inhibitor, inhibits SHIP2 activity, with an IC50 of 2 μM. SHIP2-IN-1 blocks GSK3β activation by phosphorylation at the Ser9 residue. SHIP2-IN-1 is used in the research of Alzheimer’s disease.
    SHIP2-IN-1
  • HY-158381
    PROTAC PTP1B degrader 1
    Degrader 99.37%
    PROTAC PTP1B degrader 1 (compound 75) is a CRBN-based PTP1B PROTAC degrader, with DC50 values of 0.2 μM (48 h) and 0.05 μM (72 h) (Red: PTP1B ligand Oleanolic acid (HY-N0156); Black: linker; Blue: CRBN ligand).
    PROTAC PTP1B degrader 1
  • HY-118798
    DA 3003-2
    Inhibitor 98.36%
    DA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr15 Cdc2. DA 3003-2 has the potential for the research of prostate cancer.
    DA 3003-2
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity